You are here

Intra-Articular, Sustained-Release Triamcinolone Shows Promise in OA Trial

Drug provides better pain relief versus immediate-release version (June 26)

An intra-articular, sustained-release formulation of the steroid triamcinolone acetonide (FX006, Flexion Therapeutics) provides better pain relief than immediate-release triamcinolone acetonide (TCA-IR), according to results from a phase IIb dose-ranging trial in patients with osteoarthritis (OA) of the knee.

Key study results include:

  • The optimal dose of FX006 (60 mg) showed a statistically significant and clinically meaningful improvement in the magnitude and duration of pain relief compared with TCA-IR.
  • FX006 was well-tolerated, and the systemic exposure produced by FX006 was substantially less than that of TCA-IR.
  • All secondary measures, including functional assessment, responder status, patient global impression of change, clinical global impression of change, and rescue medicine consumption, demonstrated significant improvement compared with TCA-IR.
  • The onset of pain relief occurred within hours to days, similar to that of TCA-IR.

The phase IIb trial was a double-blind, comparator-controlled study in which 228 patients were randomly assigned to receive 10 mg, 40 mg, or 60 mg of FX006 or 40 mg of TCA-IR via intra-articular knee injection. Efficacy was evaluated using the weekly mean of the average daily pain-intensity score (on the 0-to-10 Numeric Rating Scale) at weeks 1 through 12.

FX006 is a sustained-release, intra-articular formulation of triamcinolone acetonide for the treatment of mild-to-moderate knee OA. It is designed to provide prolonged pain relief while avoiding the untoward systemic effects associated with immediate-release steroids. In preclinical models of OA, FX006 demonstrated both superior efficacy to immediate-release steroids and beneficial effects on structural progression. In a phase II study of pharmacokinetics and pharmacodynamics, FX006 maintained therapeutic concentrations in the knee joint significantly longer than did TCA-IR and showed significantly reduced systemic exposure to the parent steroid compared with the IR formulation.

Source: Flexion Therapeutics; June 26, 2013.

More Headlines

Liver Fluke Infestation Affects Almost 2.5 Million People Globally
Policy Could Be Life-Changing for People With Spinal Cord Injury
Test Determines Severity of Pain, Helps Physicians Select Best Options
Intratumoral Injection Stimulates Immune Activation
Early Cancer Development May Begin in Just 30 Minutes
Diabetes and Cancer Patients Could Soon Avoid Injections